AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 32 min read$IRTC

Shrishrimal Sumi sold $186K of IRTC

Shrishrimal Sumi (EVP, Chief Risk Officer) sold 1,716 shares of iRhythm Holdings, Inc. (IRTC) at $108.19 ($0.19M total) on 2026-06-02.

Original reporting
SEC EDGAR · Shrishrimal Sumi
Published Jun 3, 2026, 8:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 3, 2026, 8:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$IRTC
Neutral
medium confidence
Mentioned
$IRTC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IRTCNeutralLow
01

Why it matters

Traders may monitor for follow-on insider activity or other catalysts, but the filing alone typically does not change valuation drivers.

02

Market read

Near-term sentiment could be slightly negative/uncertain due to disclosed insider selling, but no fundamental new information is provided.

03

What to watch

The article lacks context on total insider holdings, prior sale frequency, and whether other insiders simultaneously bought/sold, limiting inference.

Relevance 6/10Novelty 6/10Timing: Filed June 3; sale executed June 2 (post-transaction disclosure).

Background

This is an SEC Form 4 insider transaction disclosure (open-market sale) by an IRTC executive; it does not include performance or business updates.

Company-level read

Ticker impact

$IRTCNeutralMedium confidence
Context

SEC Form 4 shows IRTC Chief Risk Officer Shrishrimal Sumi sold 1,716 shares in an open-market transaction for ~$185.7K.

Expected impact

Likely limited/short-lived impact; any move would be sentiment-driven rather than driven by new fundamentals.

Evidence & confidence

The filing provides a single officer sale datapoint (size disclosed) with no stated reason, and insider sales are often non-informational absent corroborating news.

Market effects

Sector

Minimal; this is company-specific insider activity with no sector-wide regulatory/product implication stated.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Officer sales can reflect diversification or routine liquidity needs; without a 10b5-1 plan, it still may not signal negative fundamentals.

Key entities

  • issuer
    iRhythm Holdings, Inc.

    Subject of the Form 4 insider sale disclosure.

  • insider
    Shrishrimal Sumi

    EVP, Chief Risk Officer who sold 1,716 shares of IRTC.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

IRTC insider trading history →

Related articles

OCT 5
$IRTCMedAI 8/10

iRhythm completes acquisition of VitalConnect

iRhythm (IRTC) completed its acquisition of VitalConnect for $237.5M in cash and up to 423,334 shares. The deal includes a $10M working capital funding. VitalConnect's cardiac monitoring platform offers 30-day patient monitoring and 11 physiological parameters. iRhythm expects enhanced revenue growth from 2027, maintaining a 15% adjusted EBITDA margin target. Updated 2026 guidance will be provided in November 2026.

investing.com2 min
OCT 5
$IRTCMedAI 9/10

Transaction Detail The purchase consideration consisted of $237.5 million in cash, subject to customary adjustments, funded from iRhythm's balance sheet and…

iRhythm Holdings, Inc. (IRTC) filed an SEC Form 8-K — Regulation FD Disclosure. iRhythm Completes Acquisition of VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care  Combination broadens iRhythm’s cardiac monitoring portfolio, advances its multi-vitals strategy and expands iRhythm’s addressable mark

SEC EDGAR 8-K2 min
OCT 5
$IRTCHighAI 9/10

iRhythm Completes Acquisition of VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care

iRhythm (IRTC) completed its acquisition of VitalConnect, a leader in wearable biosensor and ambulatory cardiac monitoring technology. The $237.5M cash deal, plus up to 423,334 shares, is expected to expand iRhythm's cardiac monitoring portfolio, accelerate growth, and preserve its 15% adjusted EBITDA margin target for 2027. The combined entity aims to serve more patients and customers across various care settings.

globenewswire.com3 min
SEP 22
$IRTCMedAI 8/10

IRhythm Holdings, Inc., a Delaware corporation, iRhythm Technologies, Inc., a Delaware corporation and a direct wholly owned subsidiary of the Company…

iRhythm Holdings, Inc. (IRTC) filed an SEC Form 8-K — Regulation FD Disclosure. Item 7.01. Regulation FD Disclosure. As previously announced, on August 5, 2026, iRhythm Holdings, Inc., a Delaware corporation (the “Company”), iRhythm Technologies, Inc., a Delaware corporation and a direct wholly owned subsidiary of the Company (“Acquirer”), Project Vessel Mer

SEC EDGAR 8-K1 min